Life Sciences Tools & Services
43 companies across the library’s three pools, one row each. The columns are the line items this kind of business is read on; each header names its basis, and the margins and returns are medians over each company’s readable record — the through-cycle level, never one year’s print. Rows open largest first by latest-year revenue, and every column sorts both ways — the re-ordering is the reader’s own act, and a sorted view keeps its order in the address bar. The company stays in view as the columns scroll. A dash is a figure that could not be read; n/a is one that does not apply to that member; both sit at the back of a sorted column.
From the latest filings · data as of July 9, 2026.
As a group: median revenue $982M; median gross margin 52.4%; median operating margin -13.9%; median owner earnings $67M; median return on invested capital 0.8%; 20 of 43 hold net cash. Medians of this table’s own columns, over the members each applies to · data as of July 9, 2026.
| latest fiscal year, USD | median over the record | median over the record | op. cash − maintenance capex · latest FY, USD | after tax · median over the record | debt − cash & ST investments · latest FY, USD | ||||
|---|---|---|---|---|---|---|---|---|---|
| IQV | IQVIA Holdings Inc. | Life Sciences Tools & Services | $16.3B | — | 8.5% | $2.1B | 3.9% | $13.6B | |
| LH | Labcorp | Life Sciences Tools & Services | $14.0B | 28.8% | 11.7% | $1.2B | 7.7% | $5.6B | |
| DGX | Quest Diagnostics | Life Sciences Tools & Services | $11.0B | 34.7% | 14.6% | $1.4B | 10.4% | $5.3B | |
| ICLR | ICON plc | Life Sciences Tools & Services | $8.3B | 29.2% | 12.6% | $759M | 7.7% | $2.2B | |
| A | Agilent Technologies Inc. | Life Sciences Tools & Services | $6.9B | 53.6% | 18.4% | $1.3B | 16.8% | $1.3B | |
| AVTR | Avantor Inc. | Life Sciences Tools & Services | $6.6B | 33.6% | 10.0% | $495M | 6.8% | $3.6B | |
| INCY | Incyte | Life Sciences Tools & Services | $5.1B | 94.7% | 13.1% | $1.3B | 22.5% | $16.4B | |
| ILMN | Illumina Inc. | Life Sciences Tools & Services | $4.3B | 66.4% | 17.9% | $931M | 10.9% | +$143M cash | |
| MTD | Mettler-Toledo International Inc. | Life Sciences Tools & Services | $4.0B | — | 25.5% | $905M | 41.6% | $2.1B | |
| CRL | Charles River Labs | Life Sciences Tools & Services | $4.0B | — | 14.6% | $518M | 9.0% | $1.9B | |
| BRKR | Bruker | Life Sciences Tools & Services | $3.4B | 47.5% | 12.5% | $43M | 16.7% | $1.6B | |
| BRKRP | Bruker Corporation | Life Sciences Tools & Services | $3.4B | 47.5% | 12.5% | $43M | 16.7% | $1.6B | |
| EXAS | Exact Sciences | Life Sciences Tools & Services | $3.2B | 70.5% | -38.0% | $357M | -13.2% | $1.4B | |
| WAT | Waters Corporation | Life Sciences Tools & Services | $3.2B | 58.9% | 28.7% | $564M | 22.9% | $819M | |
| ULS | UL Solutions Inc. | Life Sciences Tools & Services | $3.1B | 47.9% | 16.1% | $403M | 25.9% | $196M | |
| RVTY | Revvity Inc. | Life Sciences Tools & Services | $2.9B | 66.9% | 12.5% | $509M | 5.7% | $2.3B | |
| FTRE | Fortrea Holdings Inc. | Life Sciences Tools & Services | $2.7B | — | 1.1% | $88M | 0.8% | $878M | |
| BIO | Bio-Rad | Life Sciences Tools & Services | $2.6B | 54.4% | 9.9% | $375M | 3.0% | +$331M cash | |
| MEDP | Medpace Holdings | Life Sciences Tools & Services | $2.5B | — | 17.4% | $682M | 27.3% | +$497M cash | |
| NTRA | Natera Inc. | Life Sciences Tools & Services | $2.3B | 36.7% | -47.6% | $174M | -62.2% | +$816M cash | |
| RDNT | RadNet | Life Sciences Tools & Services | $2.0B | 12.3% | 4.4% | $147M | 4.0% | $323M | |
| GH | Guardant Health Inc. | Life Sciences Tools & Services | $982M | 60.8% | -102.5% | ($233M) | -33.7% | $256M | |
| CAI | Caris Life Sciences Inc. | Life Sciences Tools & Services | $812M | — | -62.4% | $67M | — | +$420M cash | |
| NEO | NeoGenomics Inc. | Life Sciences Tools & Services | $727M | 42.3% | -13.9% | ($22M) | -7.1% | $379M | |
| TXG | 10x Genomics Inc. | Life Sciences Tools & Services | $643M | 76.7% | -31.9% | $130M | -42.0% | +$474M cash | |
| VCYT | Veracyte Inc. | Life Sciences Tools & Services | $517M | 60.9% | -24.2% | $127M | -14.8% | +$363M cash | |
| CDNA | CareDx Inc. | Life Sciences Tools & Services | $380M | 56.9% | -20.3% | $40M | -31.9% | +$143M cash | |
| CSTL | Castle Biosciences Inc. | Life Sciences Tools & Services | $344M | 79.5% | -16.8% | $28M | -18.4% | +$289M cash | |
| FLGT | Fulgent Genetics Inc. | Life Sciences Tools & Services | $323M | 54.3% | -18.6% | ($124M) | -5.4% | +$68M cash | |
| BLLN | BillionToOne Inc. | Life Sciences Tools & Services | $305M | 53.0% | -30.9% | $18M | — | +$439M cash | |
| CTKB | Cytek Biosciences Inc. | Life Sciences Tools & Services | $201M | 55.7% | -10.2% | ($9M) | -5.5% | +$91M cash | |
| PACB | Pacific Biosciences of California Inc. | Life Sciences Tools & Services | $160M | 37.1% | -161.2% | ($114M) | -67.0% | $617M | |
| GRAL | GRAIL Inc. Common Stock | Life Sciences Tools & Services | $147M | — | -1627.6% | ($300M) | — | +$250M cash | |
| NRC | NRC Health | Life Sciences Tools & Services | $137M | — | 29.1% | $19M | 43.2% | $72M | |
| MDXH | MDxHealth SA | Life Sciences Tools & Services | $108M | 51.9% | -102.3% | ($3M) | -105.9% | $47M | |
| LAB | Standard BioTools Inc. | Life Sciences Tools & Services | $85M | 49.9% | -70.1% | ($83M) | -28.7% | +$151M cash | |
| BNR | Burning Rock Biotech Limited | Life Sciences Tools & Services | $80M | 70.3% | -95.9% | ($5M) | -306.3% | +$71M cash | |
| PSNL | Personalis Inc. | Life Sciences Tools & Services | $70M | 25.6% | -80.7% | ($79M) | -48.4% | +$235M cash | |
| MASS | 908 Devices Inc. | Life Sciences Tools & Services | $56M | 51.3% | -75.5% | ($25M) | -76.0% | +$97M cash | |
| EYPT | EyePoint Inc. | Life Sciences Tools & Services | $31M | — | -246.4% | ($242M) | -207.7% | +$277M cash | |
| OABI | OmniAb Inc. | Life Sciences Tools & Services | $19M | — | -203.2% | ($37M) | -18.4% | +$26M cash | |
| ABSI | Absci Corporation | Life Sciences Tools & Services | $3M | — | -2020.2% | ($94M) | -56.1% | +$140M cash | |
| ONMD | OneMedNet Corp | Life Sciences Tools & Services | $1M | -37.0% | -711.3% | ($8M) | — | $915K |
Every figure is recomputed from the company’s own SEC or EDINET filings, the same way as on its page; the columns name facts, weigh nothing, and form no rank. Foreign filers are stated in US dollars at the dated reference rate (as of 2026-07-17) so each money column sorts on one basis; their own pages keep the records as filed. A foreign filer whose conversion terms are missing shows its money as filed and sorts to the back of the column — never a guessed conversion. Ratios and margins are currency-free.